On October 12, 2021 4D pharma plc (AIM: DDDD, NASDAQ, LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, reported that 4D management will present at the Jefferies Virtual Next Generation IBD Therapeutics Summit being held on October 19, 2021 (Press release, 4d Pharma, OCT 12, 2021, View Source [SID1234591114]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be available on the ‘Events’ section of the 4D pharma website at www.4dpharmaplc.com beginning Tuesday, October 19, 2021 at 8:00 a.m. ET (1:00 p.m. BST).

On October 12, 2021 Kytopen reported that 2021 Cell & Gene Meeting on the Mesa, organized by the Alliance for Regenerative Medicine, was a hybrid event held in-person in Carlsbad, CA on October 12 -14th and virtually on October 19th & 20th (Press release, Kytopen, OCT 12, 2021, View Source;utm_medium=rss&utm_campaign=kytopen-presents-at-the-2021-cell-gene-meeting-on-the-mesa [SID1234594172]). Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In this year company presentation, Kytopen provided a case study of our Flowfect non-viral transfection platform for ex vivo cell therapy discovery and manufacturing. The study in CD34+ stem cells & mRNA highlights our tiered approach to optimize payload and transfection parameters while confirming the robustness of the process despite donor variability and scale up for clinical relevance. In just 6 weeks, we scaled our process to transfect 200x more CD34+ stem cells in seconds while maintaining significantly high levels of cell recovery, viability, and efficiency.

The Flowfect platform is a transformative solution that eliminates the complexity of scale up in cell engineering in one flexible scalable solution. Our goal is to reduce risk while providing maximum control and flexibility to drive higher yields, faster approvals, and better outcomes for curative cellular disease treatment.

ARM’s 2021 Meeting on the Mesa attracted more than 1,700 registrants this year, including nearly 1,200 attendees at the in-person portion of the conference in Carlsbad, CA. With an approximately 40% increase in the number of registrants from 2019 and 2020, this year’s meeting was the largest in ARM’s history. The conference featured three days of live panels and presentations, as well as additional on-demand content and nearly 3,000 virtual and in-person partnering meetings.

On October 12, 2021 Eli Lilly and Company (NYSE: LLY) reported that it will announce its third-quarter 2021 financial results on Tuesday, October 26, 2021 (Press release, Eli Lilly, OCT 12, 2021, View Source [SID1234591099]). Lilly will also conduct a conference call on that day with the investment community and media to further detail the company’s financial performance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call will begin at 9 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly’s website at View Source A replay will also be available on the website following the conference call.

On October 12, 2021 CG Oncology, Inc., a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for patients with advanced cancer, reported that acceptance of an oral presentation and a poster presentation at The Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting, held virtually and in-person in Washington, DC, November 10-14, 2021 (Press release, CG Oncology, OCT 12, 2021, View Source [SID1234591115]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CG Oncology will present preliminary safety and efficacy data from CORE1, an ongoing Phase 2 clinical trial of CG0070 in combination with KEYTRUDA (pembrolizumab), for the treatment of patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).

Under a previously announced clinical collaboration with Merck relating to the investigation of CG0070 used in combination with pembrolizumab, the goal of CORE1, which will enroll up to 35 patients, is to evaluate the safety and efficacy of CG0070 plus KEYTRUDA for the treatment of NMIBC unresponsive to BCG.

More information about the study can be found at www.clinicaltrials.gov (NCT04387461).

Details of the oral presentation are as follows:

CORE1: Phase 2, Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
Abstract Number: 955
Presenter: Roger Li, M.D., Moffitt Cancer Center
Session Date & Time: Saturday, November 13, 2021 from 12:15-12:30pm EST
Category: Late-Breaking Oral Abstract Session

In addition, CG Oncology will present an overview of trial design and methodology of BOND3, an ongoing global Phase 3 trial with CG0070 as a monotherapy for the treatment of patients with NMIBC unresponsive to BCG. The goal of BOND3, which will enroll 110 patients, is to evaluate the safety and efficacy of CG0070 as a monotherapy for the treatment of NMIBC unresponsive to BCG.

More information about the study can be found at www.clinicaltrials.gov (NCT04452591).

Details of the poster presentation are as follows:

A phase 3, single-arm study of CG0070 in subjects with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG)
Abstract Number: 426
Presenter: Edward Uchio, M.D., UC Irvine Health, Department of Urology
Session Date & Time: Friday, November 12, 2021 and Saturday, November 13, 2021 from 7:00am-8:30pm EST
Category: Poster Abstract Session

Full abstracts of both presentations will be available on the SITC (Free SITC Whitepaper) website on November 10, 2021.

On October 12, 2021 Signify Health, Inc. (NYSE: SGFY), a leading value-based healthcare platform enabled by advanced analytics, technology and nationwide healthcare networks, reported that it will release its financial results for the third quarter 2021 after the market closes on Tuesday, November 9, 2021, and will hold a conference call at 8:30am ET on Wednesday, November 10, 2021 to discuss the results (Press release, Signify Health, OCT 12, 2021, View Source [SID1234591150]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pre-registration is required for participation in the conference call. Please follow the link below to pre-register. After registering, you will be provided with your access details via email.

www.incommuk.com/customers/signifyhealthquarterthree2021

A webcast of the conference call will also be available live on the investor relations section of Signify Health’s website at View Source Please go to the website at least 15 minutes prior to the call to complete the registration process.

The webcast replay will be available through January 10, 2022 on Signify Health’s website at

View Source